Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Dave & Buster’s Entertainment Inc. (“Dave & Buster’s”) (NASDAQ: PLAY).

INVESTORS OF DAVE & BUSTER’S STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

On December 10, 2024, Dave & Buster’s reported that “Chris Morris, the Company’s Chief Executive Officer (“CEO”), has tendered his resignation as CEO and Director to pursue other interests. The Board has been working with Heidrick & Struggles, a global executive search firm, for the last few months to assist in identifying the Company’s next permanent CEO and has already started meeting potential candidates.”

On this news, Dave & Buster’s stock dropped more than 14% intraday on December 11, 2024.

INVESTORS OF DAVE & BUSTER’S STOCK WITH FINANCIAL LOSSES ALSO CAN CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT.801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE DAVE & BUSTER’S SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Torrid Holdings Inc. (“Torrid” or “Torrid Holdings”) (NYSE: CURV). 

INVESTORS OF TORRID HOLDINGS STOCK STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

On December 3, 2024, Yahoo!Finance reported that “[w]omen’s plus-size apparel retailer Torrid Holdings . . . missed Wall Street’s revenue expectations in Q3 CY2024, with sales falling 4.2% year on year to $263.8 million. Next quarter’s revenue guidance of $262.5 million underwhelmed, coming in 9.3% below analysts’ estimates. Its GAAP loss of $0.01 per share was significantly below analysts’ consensus estimates.”

On this news, Torrid’s stock dropped more than 20%, and Torrid stock was down more than 30% during intraday trading on December 4, 2024. 

INVESTORS OF TORRID STOCK WITH FINANCIAL LOSSES ALSO CAN CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT.801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE TORRID SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS. 

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. (“Syros” or the “Company”) (NASDAQ: SYRS).

INVESTORS OF SYROS PHARMACEUTICALS STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SYROS SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

After the market closed on November 12, 2024, Syros announced that “[o]n November 12, 2024, an event of default occurred under the Loan and Security Agreement dated February 12, 2020 . . . between Syros Pharmaceuticals, Inc. . . . and Oxford Finance LLC (the “Lender”), as a result of the failure of the Company’s SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome patients with RARA gene overexpression to meet its primary endpoint of complete response rate.”

On this news, the stock price of Syros was down more than 86% during intraday trading on November 13, 2024. 

SYROS INVESTORS WITH FINANCIAL LOSSES ALSO CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE SYROS SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

Revance Investors With Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. 

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Revance Therapeutics Inc. (“Revance” or the “Company”) (NASDAQ: RVNC).

INVESTORS OF REVANCE STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

On September 23, 2024, Revance announced, among other things, that it “. . . received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company’s exclusive distribution agreement with Teoxane SA . . .  dated January 10, 2020 . . ..”

On this news, the stock of Revance dropped more than 7% closing at $5.365 per share on September 23, 2024.

REVANCE INVESTORS WITH FINANCIAL LOSSES ALSO CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE REVANCE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

Investors of Humacyte Stock With Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. 

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA).

INVESTORS OF HUMACYTE STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

On October 17, 2024, the stock price of Humacyte dropped more than 16%, after the FDA disclosed in a Form 483 multiple violations at the Company’s Durham, North Carolina facility, including but not limited to, inadequate quality oversight and no microbial quality assurance and testing. These violations were found during inspections that took place between April 1 through April 5, 2024.

The findings by the FDA may have run counter to statements made by the Company in May 2024 that the inspections were “very successful” and raises concerns about the Company’s transparency and commitment to regulatory compliance.

HUMACYTE INVESTORS WITH FINANCIAL LOSSES ALSO CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE HUMACYTE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

Investors of Invitation Homes Inc. Encouraged to Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating whether certain officers or directors of Invitation Homes Inc. (NYSE: INVH) failed to manage Invitation Homes in an acceptable manner, in breach of their fiduciary duties to Invitation Homes and its shareholders, and whether investors of Invitation Homes stock suffered harm.

INVESTORS OF INVITATION HOMES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

On September 24, 2024, the Federal Trade Commission (“FTC”) announced that it “. . . is taking action against Invitation Homes, the country’s largest landlord of single-family homes, for an array of unlawful actions against consumers, including deceiving renters about lease costs, charging undisclosed junk fees, failing to inspect homes before residents moved in, and unfairly withholding tenants’ security deposits when they moved out.”

According to the FTC, “Invitation Homes has agreed to a proposed settlement order that would require the company to turn over $48 million to be used to refund consumers harmed by its actions. The corporate landlord will also be required to clearly disclose its leasing prices, establish policies and procedures to handle security deposit refunds fairly, and stop other unlawful behavior.”

SHAREHOLDERS OF INVITATION HOMES SECURITIES ALSO CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE BREACH OF FIDUCIARY DUTIES INVESTIGATION AND POTENTIAL LEGAL CLAIMS.